The board of directors of China NT Pharma Group Company Limited announced unaudited consolidated earnings guidance for the year ended December 31, 2014. The Group is expected to record a net result around the breakeven region for the year ended December 31, 2014, representing a substantial improvement of the results of the Group as compared to the net loss of approximately RMB 673.5 million for the year ended December 31, 2013, mainly because no material restructuring cost is anticipated to be incurred for the year ended December 31, 2014, as compared with total restructuring costs of approximately RMB 406.1 million for the year ended December 31, 2013.